Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Shelf Life Determination in 2026: GMP Stability Focus

This article explains how stability studies GMP support shelf life justification during inspections. It examines pharmaceutical stability testing, ongoing stability programs, and common GMP inspection observations when expiration date assignment lacks scientific or regulatory support.
  • Blog, GMP, Quality Management System
GMP stability requirements illustrated through pharmaceutical stability testing, ongoing stability program review, and regulatory evaluation of expiry decisions

Good Manufacturing Practices History in 2026: How GMP Evolved Under Inspection Pressure

GMP did not emerge by chance. This article traces the history of GMP regulations, key enforcement milestones, and regulatory inspection evolution that shaped modern pharmaceutical manufacturing standards and quality systems still used to assess compliance today.
  • Blog, GMP, Quality Management System
Conceptual image illustrating the GMP evolution timeline, linking FDA GMP history, WHO GMP background, and regulatory inspection evolution to modern pharmaceutical manufacturing standards.

Vendor Audit Checklist in 2026: GMP Inspection Focus

GMP inspections increasingly focus on supplier oversight and audit execution. This article explains how vendor audit programs, supplier qualification, and risk-based evaluation influence inspection outcomes and how inspection-ready audit checklists strengthen GMP supplier control systems.
  • Blog, GMP, Quality Management System
Inspector reviewing supplier audit checklist to assess GMP vendor audit requirements, supplier compliance, and effectiveness of the vendor qualification process within a GMP supplier control system.

Pharmaceutical Documentation in 2026: GMP Inspection Focus

GMP inspections increasingly rely on documentation quality to judge system control. This article explains how regulators assess GMP records, data integrity, and traceability, and how inspection-ready documentation systems reduce audit findings and escalation risk.
  • Blog, GMP, Quality Management System
Inspector reviewing GMP documentation and deviation records to assess data integrity, ALCOA plus documentation principles, and traceability in GMP records during inspection readiness evaluation.

Adverse Drug Reactions Explained Across the Pharmacovigilance Lifecycle in 2026

Explore how adverse drug reactions evolve across the pharmacovigilance lifecycle, highlighting post-marketing safety, inspection-sensitive gaps, and structured workflows that ensure regulatory compliance, traceable oversight, and proactive risk management for pharmaceutical teams.
  • Blog, GMP, Quality Management System
Pharmacovigilance workflow showing clinical safety monitoring, post marketing adverse drug reactions, signal detection, and ADR reporting requirements for effective pharmacovigilance adverse events management

Pharmacovigilance Phases Explained Across the Product Lifecycle in 2026

A practical overview of the pharmacovigilance lifecycle, explaining how clinical safety monitoring, signal detection, and risk management planning evolve from pre-marketing activities to post-marketing oversight under current GVP compliance and regulatory inspection expectations.
  • Blog, GMP, GxP, Quality Management System
Illustration of pharmacovigilance process including signal detection, risk management plan, and GVP compliance across product lifecycle

CSV vs Annex 11: Inspection Expectations and Compliance Differences in 2026

Inspection-driven analysis of CSV vs Annex 11 highlighting why validated computerized systems still trigger findings. This article explains regulatory expectations, common inspection gaps, and how governance, data integrity, and lifecycle control shape inspection outcomes in GMP environments
  • Blog, GMP, GxP
Computerized systems inspection checklist showing data integrity controls, audit trail review, and risk-based validation expectations under EU GMP Annex 11.

GMP vs cGMP: Inspection Differences and Compliance Impact in 2026

This article explains how regulators distinguish between GMP and cGMP during inspections, why “current” compliance matters, and how governance gaps lead to inspection findings. It provides practical insight for quality, manufacturing, and compliance leaders preparing for regulatory revie
  • Blog, GMP
Regulatory inspection reviewing manufacturing process control and quality governance in pharmaceutical operations

Major Regulatory Guidelines on Isolators & RABS

Isolators and RABS both play critical roles in modern aseptic manufacturing, but their regulatory expectations differ significantly. FDA, EU, and ISO guidelines emphasize risk-based design, validated control measures, and procedural discipline.
  • Aseptic Manufacturing, GMP, Uncategorized
The isolator effectively separates the production area from personnel and the surrounding environment from contamination

Understanding Isolators in the Pharmaceutical Industry – A Simple Guide

Pharmaceutical isolators have revolutionized aseptic manufacturing by offering a controlled, contamination-free environment that enhances both product safety and operator protection.
  • Blog, GMP, GxP